Last reviewed · How we verify

NCT06801457: AN-O2-EMS

Adjuvant Cerebroprotection Using Normobaric Hyperoxia in Pre-hospital Patients with Suspected Stroke

Not yet recruiting Phase 3 Last updated 30 January 2025
What this trial tests

Phase 3 trial testing NBO in Stroke Acute in 1,000 participants. Not yet recruiting.

Timeline
1 February 2025
Primary endpoint
30 January 2028
30 January 2028

Quick facts

Lead sponsorCapital Medical University
PhasePhase 3
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment1,000
Start date1 February 2025
Primary completion30 January 2028
Estimated completion30 January 2028
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Capital Medical University

Who can join

18 and older, any sex, with Stroke Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to determine the efficacy and safety of inhaled normobaric hyperoxia therapy (NBO) beginning in the pre-hospital setting in patients with suspected acute cerebral ischemia (ACI) due to large vessel occlusion presenting within 6 hours of symptom onset.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Multimodal Neuroprotection in Ischemic Stroke: Emerging Non-Pharmacological Interventions from Bench to Bedside.
    Cui J, Yang J, Liu L, Liu X, et al · · 2025 · PMID 41154205 · DOI 10.3390/brainsci15101111

Verify or expand the search:

Other trials of NBO

Trials testing the same drug.

Other recruiting trials for Stroke Acute

Currently open trials in the same condition.

Other Capital Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06801457.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing